Veracyte, Inc. (VCYT)
| Market Cap | 4.28B +100.2% |
| Revenue (ttm) | 541.74M +16.9% |
| Net Income | 88.01M +166.3% |
| EPS | 1.08 +160.6% |
| Shares Out | 79.79M |
| PE Ratio | 49.68 |
| Forward PE | 30.54 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,155,430 |
| Open | 51.96 |
| Previous Close | 51.29 |
| Day's Range | 51.92 - 53.81 |
| 52-Week Range | 22.61 - 53.81 |
| Beta | 1.98 |
| Analysts | Buy |
| Price Target | 49.10 (-8.45%) |
| Earnings Date | Aug 5, 2026 |
About VCYT
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its n... [Read more]
Financial Performance
In 2025, Veracyte's revenue was $517.15 million, an increase of 16.01% compared to the previous year's $445.76 million. Earnings were $66.35 million, an increase of 174.89%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for VCYT stock is "Buy." The 12-month stock price target is $49.1, which is a decrease of -8.45% from the latest price.
News
Veracyte Transcript: AGM 2026
The meeting confirmed quorum, elected all nominated directors, ratified the auditor, approved executive compensation, and passed an amendment to the equity incentive plan. No questions were submitted, and caution was advised regarding forward-looking statements.
Veracyte Transcript: Jefferies Global Healthcare Conference 2026
Strong Q1 results drove raised guidance, with double-digit growth in Afirma and Decipher, and EBITDA margins above target. New launches, including Prosigna and TrueMRD, are supported by robust clinical data and a disciplined investment approach. Market expansion is driven by innovation, data strategy, and operational efficiency.
Veracyte Transcript: 46th Annual William Blair Growth Stock Conference
Significant growth and innovation were highlighted, including the launch of Prosigna and TrueMRD, both backed by robust clinical evidence. Financial performance exceeded targets, with strong profitability and a positive outlook for 2026. Prosigna's OPTIMA data is seen as practice-changing.
Veracyte Slides: 46th Annual William Blair Growth Stock Conference
Veracyte has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
Veracyte assumed with an Outperform at Wolfe Research
Wolfe Research assumed coverage of Veracyte (VCYT) with an Outperform rating and price target of $55, up from $50. The company’s testing assets, Afirma and Decipher, bring “rare comfort in…
Veracyte Transcript: Study update
OPTIMA phase III results show Prosigna enables most high-risk early breast cancer patients to avoid chemotherapy without compromising outcomes, with robust evidence across subgroups. ENZAMET confirms Decipher Prostate’s predictive value in metastatic prostate cancer, supporting more precise treatment.
Veracyte Slides: Study update
Veracyte has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
Veracyte announces U.S. commercial launch of Prosigna ROR test
Veracyte (VCYT) announced the U.S. commercial launch of the Prosigna Breast Risk of Recurrence, ROR, test. The Prosigna test determines a patient’s ROR score and estimates the 10-year probability of…
Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #BreastCancer--Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.
Veracyte announces results from Enzamet trial presented at 2026 ASCO meeting
Veracyte (VCYT) announced results from the Enzamet trial presented at the 2026 ASCO Annual Meeting. The analysis demonstrates that the Decipher Prostate test identifies which men with metastatic prost...
ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCO26--ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate ...
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte's Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCO26--OPTIMA Trial Delivers Practice-Changing Evidence that Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoi...
Veracyte genomic test identifies breast cancer patients who can skip chemo
Today we feature studies to be presented at the year's most important cancer conference, the upcoming American Society of Clinical Oncology meeting in Chicago, all with the potential to be practice-c...
Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that it will host a conference call and webcast on Monday, June 1, 20...
OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCO26--OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer.
Veracyte to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that the company will be participating in the following investor conferences. William Blair 46th Annual Grow...
Veracyte’s TrueMRD Monitoring Test receives coverage from CMS
Veracyte (VCYT) announced that its TrueMRD Monitoring Test has received coverage from the Centers for Medicare & Medicaid Services’, CMS, Molecular Diagnostics Services Program for patients with muscl...
Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #BladderCancer--Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer.
Veracyte price target raised to $42 from $40 at Canaccord
Canaccord analyst Kyle Mikson raised the firm’s price target on Veracyte (VCYT) to $42 from $40 and keeps a Hold rating on the shares. The firm said the target increase…
Veracyte price target raised to $52 from $48 at UBS
UBS raised the firm’s price target on Veracyte (VCYT) to $52 from $48 and keeps a Buy rating on the shares.
Veracyte Earnings Call Transcript: Q1 2026
Q1 2026 saw 21% revenue growth and strong profitability, driven by Decipher and Afirma test expansion. Guidance for 2026 was raised, with new product launches (Prosigna LDT, TrueMRD) expected to fuel future growth. Robust clinical evidence and operational improvements underpin long-term momentum.
Veracyte Earnings release: Q1 2026
Veracyte released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Veracyte Slides: Q1 2026
Veracyte has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
Veracyte Quarterly report: Q1 2026
Veracyte has published its Q1 2026 quarterly earnings report on May 5, 2026.
Veracyte Announces First Quarter 2026 Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2026. “We had...